Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 1529564, 9 pages
Research Article

CYP1B1 G199T Polymorphism Affects Prognosis of NSCLC Patients with the Potential to Be an Indicator and Target for Precise Drug Intervention

1Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
2Lung Cancer Diagnosis and Treatment Center, Dalian, Liaoning 116011, China
3Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai, Hebei 054031, China
4China National Research Institute of Food & Fermentation Industries, Beijing 100015, China

Correspondence should be addressed to Jinxiu Li; nc.ude.umd@uixnijil and Chundong Gu; nc.ude.umd@gnodnuhcug

Received 31 December 2016; Accepted 22 January 2017; Published 9 March 2017

Academic Editor: Alexander N. Orekhov

Copyright © 2017 Fengzhou Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


CYP1B1 gene single nucleotide polymorphisms G119T, C432G, and A453G were tested among 164 NSCLC patients treated by Video-Assisted Thoracoscopic Surgery. After a follow-up period of 5 years, it was found that CYP1B1 G119T mutant genotypes were related to a higher risk of tumor recurrence and death after surgical resection. However, C432G and A453G genotypes had no influence on long-term prognosis of the study cohort. Thus, G199T alleles are supposed to be an auxiliary predictor for prognosis of NSCLC patients and a potential target for precise drug intervention, as well as a candidate for further anticancer drug research.